Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wijdicks, E. F.
Right arrow Articles by Krom, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wijdicks, E. F.
Right arrow Articles by Krom, R. A.

Neurology, Vol 45, Issue 11 1962-1964, Copyright © 1995 by American Academy of Neurology

ARTICLES

Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression

EF Wijdicks, RH Wiesner and RA Krom
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

We studied the clinical features, blood levels of cyclosporine, and neuroimaging findings in 46 patients with cyclosporine neurotoxicity after liver transplantation. The clinical presentation of cyclosporine neurotoxicity was characterized by tremulousness and restlessness in all patients and was associated with acute confusional state and psychosis in 20 patients, seizures in eight, speech apraxia or action myoclonus speech in three, and cortical blindness in two. In 35 patients, cyclosporine neurotoxicity occurred during IV treatment. Neuroimaging studies showed only minor white matter abnormalities in two patients despite dramatic clinical presentations, including speech difficulties, seizures, and cortical blindness. In only 19 of 31 patients (61%) did trough levels of cyclosporine suggest neurotoxicity. Neurologic findings were reversible in all patients after cyclosporine was withheld and then given in lower dosage. In three patients, substituting FK 506 did not result in neurotoxicity.


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
J. L. Taylor and S. M. Palmer
Critical Care Perspective on Immunotherapy in Lung Transplantation
J Intensive Care Med, December 1, 2006; 21(6): 327 - 344.
[Abstract] [PDF]

Home page
 FocusHome page
A. F. DiMartini, M. A. Dew, and P. T. Trzepacz
Organ Transplantation
Focus, April 1, 2005; 3(2): 280 - 303.
[Full Text] [PDF]

Home page
 NeurologyHome page
B. V. Maramattom and E. F.M. Wijdicks
Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients
Neurology, November 23, 2004; 63(10): 1958 - 1959.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
N. J. Serkova, U. Christians, and L. Z. Benet
Biochemical Mechanisms of Cyclosporine Neurotoxicity
Mol. Interv., April 1, 2004; 4(2): 97 - 107.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. I. Buis, R. H. Wiesner, R. A.F. Krom, W. K. Kremers, and E. F.M. Wijdicks
Acute confusional state following liver transplantation for alcoholic liver disease
Neurology, August 27, 2002; 59(4): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. F. M. Wijdicks, L. J. Dahlke, and R. H. Wiesner
Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients
Neurology, May 1, 1999; 52(8): 1708 - 1708.
[Abstract] [Full Text]

Home page
 CirculationHome page
L. W. Miller
Cyclosporine-Associated Neurotoxicity: The Need for a Better Guide for Immunosuppressive Therapy
Circulation, September 15, 1996; 94(6): 1209 - 1211.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.